Guide de travaux pratiques · Neuropeptides
What Is Adamax? Adamantane-Modified Semax Analogue Research Overview
What is Adamax? It is a designer analogue of Semax, Ac-Met-Glu-His-Phe-Pro-Gly-Pro with an adamantane-containing C-terminal group, with the formula C50H69N11O11S and a mass of about 1032 Da. This guide explains what is chemically defined, why two different molecules are sold under the same name, and why no peer-reviewed study of Adamax itself was found.
Points clés à retenir
- Adamax (1032 Da) is Ac-MEHFPGP linked to an adamantane-containing C-terminal unit, formula C50H69N11O11S, molar mass 1032.23 g/mol.
- A second material sold as “Adamax” at 984 Da is a different molecule, acetylated Semax extended with Ala-Gly and no adamantane, so mass must be confirmed.
- No peer-reviewed literature on Adamax itself and no CAS number were found; the rationale is extrapolated from Semax and the research peptide P021.
- It has been identified as a designer drug in border seizures and has been proposed for prescription classification in New Zealand.
What is Adamax?
So, what is Adamax? Adamax is a synthetic peptide derivative described as a designer analogue of Semax, modified with the N-terminal and C-terminal modifications found in Peptide 021 (Wikipedia entry for Adamax). Its structure is given as Ac-MEHFPGP linked to an adamantane-containing unit with a terminal amide. It is not a recognised pharmaceutical, and it is a recent research-market compound. Its parent, Semax, is covered in What is Semax.
À usage exclusivement scientifique. Cette présentation synthétise les résultats publiés issus de recherches en laboratoire et sur des animaux. Baltic Peptides fournit ce composé à des chercheurs qualifiés pour des recherches in vitro et précliniques ; il ne s'agit pas d'un médicament et il n'est pas destiné à un usage humain ou vétérinaire.
Structure chimique et caractéristiques techniques
| Biens immobiliers | Adamax 1032 Da | « Adamax » 984 Da |
|---|---|---|
| Formule | C50H69N11O11S | C44H61N11O13S |
| Masse moyenne | 1032.23 g/mol | 984.1 g/mol |
| Structure | Ac-MEHFPGP + adamantane unit, C-terminal amide | Ac-MEHFPGPAG-OH, no adamantane |
| Numéro CAS | None assigned | None assigned |
I confirmed that the formula for the 1032 Da form equals acetylated MEHFPGP joined to 3-aminoadamantane-1-carboxamide, which is the connectivity shown in the Wikipedia entry’s SMILES; the supplier states that the exact connectivity has not been published, so treat the depiction as unconfirmed. The 984 Da formula equals Ac-MEHFPGPAG-OH. The two share a Semax core and N-acetyl cap and differ in the C-terminus, so they are not interchangeable.
Historique des découvertes et de la recherche
Adamax appeared in the research-peptide market in the mid-2020s. The Wikipedia entry for Adamax states that it has been identified as a designer drug in border seizures and that its classification as a prescription medicine in New Zealand has been suggested, citing a June 2025 submission to Medsafe’s Medicines Classification Committee. I did not open that submission.
Its lineage has two sources: Semax from Russian neuropeptide research, and P021, an adamantylglycine-modified research peptide derived from ciliary neurotrophic factor, according to the supplier. No discovery paper for Adamax was found.
Design rationale and what is unknown
Design hypotheses
The N-acetyl cap is expected to slow aminopeptidase cleavage, and the bulky lipophilic adamantane cage is expected to raise lipophilicity and resist enzymatic breakdown. N-terminal acetylation is known to protect some peptides from DPP-IV (N-terminal acetylation protects GLP-1-(7-34)-amide from DPP-IV degradation), but protection is peptide-specific.
What is not established
No receptor, pathway or pharmacokinetic study of Adamax was found. The BDNF/TrkB framing in supplier materials is extrapolated from Semax and should be treated as a hypothesis. For that reason, this article draws the diagram as composition and status, not as a signalling mechanism.
Principaux domaines de recherche
- Analytical chemistry: confirming mass and separating the 1032 Da and 984 Da materials.
- Stability and lipophilicity assays: comparison with Semax and N-Acetyl Semax Amidate in vitro.
- Structure-activity design: use of adamantane cages in peptide modification.
- Parent-compound research: Semax studies, in the Semax article.
Ce que révèlent réellement les études publiées
| Type de preuve | Ce qui est rapporté |
|---|---|
| Données chimiques | Formula and mass are defined; connectivity is shown in one encyclopaedic source and not independently published. |
| Peer-reviewed studies | None found for Adamax itself. |
| Parent compound | Semax literature exists but is not transferable. |
| Réglementation | No approval anywhere according to the supplier; reported as a designer drug in border seizures. |
Claims of large potency gains over Semax circulate in vendor material. None was found in the peer-reviewed literature.
Limites scientifiques et questions en suspens
- No peer-reviewed study of Adamax itself was found.
- Two different molecules are sold under the same name, and the supplier states that the exact connectivity of the 1032 Da form has not been published.
- The adamantane benefits are design hypotheses.
- It has no CAS number, no approval, and has been reported in border seizures as a designer drug.
Considérations relatives aux analyses et aux travaux de laboratoire
Because two molecules share the name, mass confirmation is the key identity test: the 1032 Da form should show about 1032.2 Da, and the 984 Da material about 984.1 Da. HPLC should resolve Met-sulfoxide (+16 Da) because methionine remains exposed. The adamantane cage makes the molecule markedly more hydrophobic, so it retains longer on reverse-phase HPLC than Semax.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the Adamax product page.
Sources et lectures complémentaires
- Adamax, Wikipedia (citing the June 2025 Medsafe submission “Classification of Unscheduled Peptides”). Wikipedia
- L'acétylation N-terminale protège le peptide de type glucagon GLP-1-(7-34)-amide contre la dégradation induite par la DPP-IV, lui permettant ainsi de conserver sa capacité à libérer de l'AMPc et de l'insuline (2008). PubMed
- Conception et administration rationnelles des peptides synthétiques (revue de 2026), sur les groupes terminaux. PMC
Tous les produits de la gamme « Baltic Peptides » sont destinés exclusivement à la recherche en laboratoire. Il ne s'agit ni de médicaments, ni de compléments alimentaires, ni d'aliments, et ils ne sont pas destinés à être utilisés chez l'homme ou chez l'animal. Cet article résume les recherches publiées à des fins purement pédagogiques et ne décrit aucune utilisation chez l'homme.
FAQ
Questions fréquentes
What is Adamax?
Quelle est la différence entre l'Adamax 1032 Da et le 984 Da ?
What is the molecular weight of Adamax?
Is there published research on Adamax?
What does the adamantane group do?
How is Adamax different from N-Acetyl Semax Amidate?
Is Adamax an approved medicine?
Continuez à lire
Lectures complémentaires
Adamax (1 032 Da)
Current batches, formats and the COA for Adamax.
Qu'est-ce que le Semax ?
The ACTH(4-7)-derived parent peptide.
Qu'est-ce que l'amidate de N-acétyl-Semax ?
The simple double-capped Semax form, for comparison.
Research-grade Adamax, tested before it ships
HPLC s indépendantes et résultats de spectrométrie de masse pour chaque lot expédié depuis l'UE.
